Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis
Sofía Ramiro, Josef S Smolen, Robert Landewé, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 3, pp. 490-498
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Laure Gossec, Josef S Smolen, Sofía Ramiro, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 3, pp. 499-510
Open Access | Times Cited: 885
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 834
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe, Robert Landewé, C. Daïen, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 6, pp. 948-959
Open Access | Times Cited: 509
Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases
Ashwin N. Ananthakrishnan, Chengwei Luo, Vijay Yajnik, et al.
Cell Host & Microbe (2017) Vol. 21, Iss. 5, pp. 603-610.e3
Open Access | Times Cited: 374
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
Siddharth Singh, Antonio Facciorusso, Abha G. Singh, et al.
PLoS ONE (2018) Vol. 13, Iss. 5, pp. e0195123-e0195123
Open Access | Times Cited: 236
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease, Alice B. Gottlieb, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 9, pp. 1550-1558
Open Access | Times Cited: 196
French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults
F. Amatore, A. Villani, M. Tauber, et al.
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 3, pp. 464-483
Open Access | Times Cited: 191
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 778-786
Open Access | Times Cited: 169
Treatment guidelines in psoriatic arthritis
Alexis Ogdie, Laura C. Coates, Dafna D. Gladman
Lara D. Veeken (2019) Vol. 59, Iss. Supplement_1, pp. i37-i46
Open Access | Times Cited: 154
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 760-774
Open Access | Times Cited: 20
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J. Mease, Philip Helliwell, Kasper Fjellhaugen Hjuler, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 2, pp. 185-193
Open Access | Times Cited: 108
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future
Daniela Pugliese, Carla Felice, Alfredo Papa, et al.
Expert Review of Clinical Immunology (2016) Vol. 13, Iss. 3, pp. 223-233
Closed Access | Times Cited: 100
2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis
Daniel Wendling, Cédric Lukas, Clément Prati, et al.
Joint Bone Spine (2018) Vol. 85, Iss. 3, pp. 275-284
Closed Access | Times Cited: 87
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature
Laure Gossec, Dennis McGonagle, Т. В. Коротаева, et al.
The Journal of Rheumatology (2017) Vol. 45, Iss. 1, pp. 6-13
Open Access | Times Cited: 87
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
Scott M. Whitlock, Clinton Enos, April W. Armstrong, et al.
Journal of the American Academy of Dermatology (2018) Vol. 78, Iss. 2, pp. 383-394
Closed Access | Times Cited: 82
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
Laure Gossec, Laura C. Coates, Maarten de Wit, et al.
Nature Reviews Rheumatology (2016) Vol. 12, Iss. 12, pp. 743-750
Closed Access | Times Cited: 77
Liver Illness and Psoriatic Patients
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, et al.
BioMed Research International (2018) Vol. 2018, pp. 1-12
Open Access | Times Cited: 65
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
Elsa Vieira‐Sousa, Pedro Augusto Alves, Ana Maria Rodrigues, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 4, pp. 490-498
Open Access | Times Cited: 54
Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients
Maria Effenberger, Simon Reider, Silvio Waschina, et al.
Journal of Crohn s and Colitis (2020) Vol. 15, Iss. 1, pp. 88-98
Open Access | Times Cited: 51
Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
Emma Dures, Sarah Hewlett, Jane Lord, et al.
Patient (2017) Vol. 10, Iss. 4, pp. 455-462
Open Access | Times Cited: 57
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
Paweł Kawalec, Przemysław Holko, Paweł Moćko, et al.
Rheumatology International (2017) Vol. 38, Iss. 2, pp. 189-201
Open Access | Times Cited: 56
Psoriatic arthritis and physical activity: a systematic review
J. Kessler, Mickaël Chouk, T. Ruban, et al.
Clinical Rheumatology (2021) Vol. 40, Iss. 11, pp. 4379-4389
Closed Access | Times Cited: 36
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review
Lucia Sara D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, et al.
PharmacoEconomics (2018) Vol. 36, Iss. 5, pp. 567-589
Closed Access | Times Cited: 45
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation
Mark Corbett, Fadi Chehadah, Mousumi Biswas, et al.
Health Technology Assessment (2017) Vol. 21, Iss. 56, pp. 1-326
Open Access | Times Cited: 40
Secukinumab: A Review in Psoriatic Arthritis
Matt Shirley, Lesley J. Scott
Drugs (2016) Vol. 76, Iss. 11, pp. 1135-1145
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top